Online inquiry

IVTScrip™ mRNA-Anti-VSIR, JNJ-61610588(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ9588MR)

This product GTTS-WQ9588MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets VSIR gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_022153.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 64115
UniProt ID Q9H7M9
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-VSIR, JNJ-61610588(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ9588MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ333MR IVTScrip™ mRNA-Anti-CD27, 1F5(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA 1F5
GTTS-WQ6956MR IVTScrip™ mRNA-Anti-VEGFA, ESBA-1008(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ESBA-1008
GTTS-WQ13584MR IVTScrip™ mRNA-Anti-IL13, QAX-576(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA QAX-576
GTTS-WQ2265MR IVTScrip™ mRNA-Anti-F, ALX-0171(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ALX-0171
GTTS-WQ10574MR IVTScrip™ mRNA-Anti-ANGPT2, LY-3127804(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA LY-3127804
GTTS-WQ5314MR IVTScrip™ mRNA-Anti-ALCAM, CD166 AADC(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CD166 AADC
GTTS-WQ14217MR IVTScrip™ mRNA-Anti-IL17A, RG4934(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA RG4934
GTTS-WQ5338MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, CD20-TCB (2:1)(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CD20-TCB (2:1)
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW